The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Learn more about:
Related Clinical Trial
Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma Umbrella Biomarker-Guided Therapy in NPC Magnifying NBI for Occult NPC Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma Treatment of Bevacizumab Followed by Steroid in RN Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation Individualized Carbon-Ion Radiotherapy for Patients With Locally Recurrent Nasopharyngeal Carcinoma Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC With Induced Chemotherapy Resistance LMP2-Specific IL12-secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer Bupropion Hydrochloride or Patient’s Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Study of DC-CTL Combined With CIK for Advanced Solid Tumor Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Assessment of New Radiation Oncology Technologies and Treatments Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Acupuncture for Prevention of Radiation-Induced Xerostomia Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases Applying PET/MR in Oncology – a Prospective Project Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Trial of E10A in Head and Neck Cancer NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC Hepatic Artery Infusion Pump for NPC Liver Metastases A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients Plasma EBV DNA Monitoring in Post-treatment NPC Patients Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy Study of DC-CIK to Treat NPC Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer NBI to Detect Post-RT Mucosal Residual NPC Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study Using Massage of Maxillofacial and Oral Cavity to Prevent Radioactive Oral Mucositis Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC) Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC Acute Radiation Oral Mucositis in Nasopharyngeal Carcinoma(NPC) Patients Treated With Combined Radio-Chemotherapy Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) PET and MRI in Prognosis Prediction of NPC Reactivating NK Cells in Treating Refractory Head and Neck Cancer Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients Ultrasensitive Positron Emission Tomography in NPC Patients Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC) Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Molecular Mechanism of Nasopharyngeal Carcinoma Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 Individualized Elective Neck Irradiation Based on MRI in NPC Patients Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma 3DV+TPS Software Outlines the Radiotherapy of Nasopharyngeal Carcinoma Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis 3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) Carbon-Ion Radiotherapy Plus Camrelizumab With or Without Apatinib for Locally Recurrent Nasopharyngeal Carcinoma Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma A Study of Nasopharyngeal Carcinoma From Guangdong A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in Nasopharyngeal Carcinoma Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC) Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma Weekly Plasma EBV DNA for Non-metastatic Nasopharyngeal Carcinoma Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma MK-2206 in Recurrent Nasopharyngeal Carcinoma Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma Serial Plasma EBV DNA for Nasopharyngeal Carcinoma Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients Endostar for Locally Recurrent Nasopharyngeal Carcinoma Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal Carcinoma Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma Intestinal Flora Sequencing for Nasopharyngeal Carcinoma Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma Patients A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Administration of Epstein Barr Virus – Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma SOX as Salvage Treatment in Nasopharyngeal Carcinoma Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma. Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma Nimotuzumab for Recurrent Nasopharyngeal Carcinoma Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma Screening for Nasopharyngeal Carcinoma in High Risk Populations EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer PET/MR in Locally Advanced Nasopharyngeal Carcinoma Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer Nasopharyngeal Carcinoma Screening in Zhongshan City Nasopharyngeal Carcinoma Post IMRT To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer Parotid-sparing IMRT for Nasopharyngeal Cancer Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Nasopharyngeal Carcinoma A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer. Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli

Brief Title

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Official Title

A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma

Brief Summary

      The purpose of this study is to preliminarily evaluate anti-tumor activity of a Recombinant
      Humanized Anti-PD-1 Monoclonal Antibody for Infusion (JS001) in treating advanced gastric
      adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and head and
      neck squamous cell carcinoma and to determine the recommended phase II dose (RP2D)
    

Detailed Description

      Overall Design:

      This is a multicenter, open-label, phase Ib/II clinical study of Toripalimab Injection
      (JS001) in patients with gastric adenocarcinoma (GC), esophageal squamous cell carcinoma
      (ESCC), nasopharyngeal carcinoma (NPC), or head and neck squamous cell carcinoma (HNSCC). On
      the basis of the results of safety and pharmacokinetic data in the phase I study of JS001, 3
      mg/kg is determined as the recommended dose of the 2-week monotherapy regimen, and no study
      on the 10 mg/kg cohorts will be conducted any more. And the corresponding 240 mg and 360 mg
      are determined as the corresponding exploratory doses of the 3-week combined treatment
      regimens.

      Eligible subjects will be selected based on the inclusion and exclusion criteria: subjects
      with gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or
      head and neck squamous cell carcinoma (cohort 1, 2, 3, 4, respectively) will receive
      treatment at the dose of 3 mg/kg. While subjects with advanced gastric adenocarcinoma,
      esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell
      carcinoma (cohort 5, 6, 7, 8, respectively), who have not received any treatment before, will
      be treated with the corresponding 3-week regimen of standard first-line chemotherapy combined
      with JS001 240 mg or 360 mg .

      Study Treatment:

      The study on the 3 mg/kg cohorts is planned to be conducted first in cohort 1, 2, 3, 4 in
      this trial. After enrollment, the subjects will receive study treatment once every 2 weeks
      (Q2W) with 4 weeks as a cycle, until absence of further benefits judged by the investigator,
      disease progression, occurrence of intolerable toxicity, investigator's decision, withdrawal
      of informed consent by the subject, or death.

      The study of cohort 5, 6, 7, and 8 will be carried out in the sites designated by the
      sponsor. Subjects will receive corresponding regimen of standard first-line chemotherapy
      combined with JS001 240 mg or 360 mg once every 3 weeks (Q3W) (see Section 3.1 Overall Design
      for details). JS001 240 mg or 360 mg Q3W can be administrated after the end of chemotherapy
      until absence of further benefits judged by the investigator, disease progression, occurrence
      of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the
      subject, or death.

      If the subject experiences disease progression but the subject can still obtain clinical
      benefit from the study treatment of JS001 according to the investigator, the subject can
      continue the study treatment if an approval is obtained after discussion between the
      investigator and the medical monitor from the sponsor or the authorized CRO. If the subject
      develops disease progression for a second time, he/she should permanently withdraw from the
      study treatment.

      Tumor Assessment:

      During the study, for cohort 1, 2, 3, and 4, tumor responses will be evaluated every 8 weeks
      in the first year according to RECIST 1.1, and every 12 weeks thereafter. Tumor responses
      will also be evaluated according to irRECIST at the same frequency with that conducted
      according to RECIST 1.1 until disease progression, death or loss of follow up (whichever
      comes first). For cohort 5, 6, 7, and 8, tumor responses will be evaluated every 6 weeks (± 3
      days) in the first year according to RECIST 1.1 and irRECIST, and every 12 weeks thereafter
      until disease progression, death or loss of follow up (whichever comes first).

      The radiographic data of the subjects will be collected for review by IRC. The IRC will
      evaluate the corresponding study endpoints based on tumor responses, but no such evaluation
      is planned for cohort 5, 6, 7 and 8.

      Pharmacokinetics:

      At least 10 of the subjects (no requirements on indications) in JS001 3 mg/kg cohorts at the
      sponsor-designated study sites should complete the pharmacokinetic blood sampling in the
      first 3 cycles of study treatment until 60 days after the end of study treatment. If a
      subject did not complete the scheduled sample collection in the first 3 cycles of study
      treatment due to any reason, another subject should be added.

      Corresponding pharmacokinetic blood samplings will also be conducted for cohort 5, 6, 7, and
      8, to evaluate the pharmacokinetic characteristics of JS001 used in the combined treatment
      with chemotherapy. At least 3 patients will be selected for blood sampling in each cohort.

      Acquisition of Tumor Tissue Specimens:

      Subjects with esophageal squamous cell carcinoma, gastric adenocarcinoma (including
      adenocarcinoma at esophageal-gastric conjunction), nasopharyngeal carcinoma, or head and neck
      squamous cell carcinoma must provide acceptable tumor tissue specimens (fresh tumor tissue
      specimens for biopsy before enrollment are preferred) prior to enrollment for future use in
      subsequent exploratory studies.

      Any subject with the response confirmed as partial response (PR) and/or progressive disease
      (PD) is encouraged to voluntarily participate in the selectable biomarkers study if tumor
      tissues can be obtained from him/her. And in the selectable biomarkers study, they will
      provide tumor tissues for exploratory study on the correlation between tumor markers and the
      level of anti-tumor responses.

      All the tumor tissue specimens provided will be sent to the designated central laboratory for
      evaluation.

      End of Study:

      The primary endpoint of the study is ORR. The study will be completed at 12 months after the
      last patient in and data analysis will be conducted then. If by that time there are still
      some subjects receiving study treatment, these subjects will be transferred to an extension
      study to continue the study treatment until absence of further benefits judged by
      investigator, disease progression, occurrence of intolerable toxicity, investigator's
      decision, withdrawal of informed consent by subject, or death.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

Secondary Outcome

 Duration of response (DOR)

Condition

Gastric Adenocarcinoma

Intervention

3 mg/kg anti-PD-1 mAb JS001 Q2W

Study Arms / Comparison Groups

 3 mg/kg anti-PD-1 mAb JS001 Q2W
Description:  Subjects will be eligible for this study after they fulfill the inclusion criteria and exclusion criteria. Subjects diagnosed as the gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma will receive treatment at the dose of 3 mg/kg.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

403

Start Date

December 2016

Completion Date

October 31, 2021

Primary Completion Date

September 30, 2019

Eligibility Criteria

        "Inclusion Criteria Subjects may be entered in the study only if they meet all of the
        following criteria:

          1. Fully understand the study and signed the Informed Consent Form (ICF) voluntarily;

          2. Subjects with histologically and/or cytologically confirmed advanced and/or metastatic
             gastric adenocarcinoma (including adenocarcinoma at esophageal-gastric conjunction),
             esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck
             squamous cell carcinoma, who meet the following conditions (not applicable to cohort
             5, 6, 7, and 8):

             Subjects with gastric adenocarcinoma must have received at least one line of
             anti-tumor treatment for advanced gastric adenocarcinoma and have documented tumor
             progression or be intolerable to the current available chemotherapy regimen. Subjects
             who have recurrence or metastasis within 6 months after completion of concomitant
             adjuvant or neoadjuvant chemotherapy of radical operation are eligible to this study;
             Subjects with esophageal squamous cell carcinoma must have received at least one line
             of treatment for advanced esophageal squamous cell carcinoma (including but not
             limited to anticancer drug treatment or radio-chemotherapy) and have documented tumor
             progression or be intolerable to the current chemotherapy regimen. Subjects who have
             recurrence or metastasis within 6 months after completion of concomitant adjuvant or
             neoadjuvant therapy (including but not limited to chemotherapy or radio-chemotherapy)
             of radical operation are eligible to this study;

             Subjects with nasopharyngeal carcinoma or head and neck squamous cell carcinoma who
             have received at least one line of treatment for advanced nasopharyngeal carcinoma or
             head and neck squamous cell carcinoma (including but not limited to anticancer drug
             treatment or radio-chemotherapy) and have documented tumor progression or be
             intolerable to other current chemotherapy regimens. Subjects with recurrence or
             metastasis within 6 months after completion of concomitant adjuvant or neoadjuvant
             radio-chemotherapy of radical operation are eligible to this study (only applies for
             Version 4.1 and the previous ones); while for the working protocol version 5.0,
             subjects with nasopharyngeal carcinoma can be enrolled only if they meet the following
             criteria:

             subjects having received at least two lines of treatment for advanced nasopharyngeal
             carcinoma (including but not limited to anticancer drug treatment and
             radio-chemotherapy), who are confirmed to have tumor progression or be intolerable to
             other current chemotherapy regimens; adjuvant or neoadjuvant radio-chemotherapy after
             radical surgery can be considered as one line of treatment if tumor recurrence or
             metastasis occurred within 6 months after the end of the radio-chemotherapy.

          3. At least one measurable lesion (according to RECIST 1.1); Note: Any lesion which
             received radiotherapy treatment previously cannot be regarded as a target lesion,
             unless that it has definitely progressed after radiotherapy.

          4. Agree to provide archived tumor tissue specimens or have biopsy to collect tumor
             tissues for PD-L1 IHC measurement in the central laboratory;

          5. Males or females aged between 18 and 75 years old;

          6. ECOG score of 0-1;

          7. Life expectancy ≥ 3 months;

          8. The results of laboratory tests performed within 7 days prior to enrollment must meet
             the following criteria:

               1. Neutrophils ≥ 1.5×109/L (not applicable to cohort 5, 6, 7, and 8);

               2. Platelets ≥ 75×109/L (not applicable to cohort 5, 6, 7, and 8);

               3. Hemoglobin ≥ 90 g/L (without receiving infusion of concentrated red blood cells
                  within 2 weeks);

               4. Serum creatinine ≤ 1.5× upper limit of normal (ULN), or creatinine clearance > 50
                  mL/min (not applicable to cohort 5, 6, 7, and 8);

               5. Serum total bilirubin ≤ 1.5×ULN (total bilirubin ≤ 3×ULN are acceptable for
                  subjects with Gilbert syndrome);

               6. Both AST and ALT ≤ 2.5×ULN; ALT and AST ≤ 5×ULN are acceptable for subjects with
                  liver metastasis;

          9. Serum pregnancy test result must be confirmed as negative for women of childbearing
             potential within 28 days prior to enrollment and the subjects must agree to take
             effective contraception measures throughout the study treatment period until 60 days
             after the end of study treatment. Women of childbearing potential are defined as women
             with sexual maturity, who meet any of the following conditions: 1) no hysterectomy or
             bilateral oophorectomy; 2) without natural menopause for a consecutive 24 months
             (patients with menopause after cancer treatment may also have childbearing potential)
             (i.e. menstruation occurred at any time during the previous consecutive 24 months)
             (not applicable to cohort 5, 6, 7, and 8).

        Female partners of childbearing potential of the male subjects should also follow the
        contraception requirements.

        Other special inclusion criteria for cohort 5, 6, 7, and 8.

          1. Subjects with histologically and/or cytologically confirmed advanced and/or metastatic
             gastric adenocarcinoma (including adenocarcinoma at esophageal-gastric conjunction),
             esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck
             squamous cell carcinoma, who meet any of the following conditions:

               1. Subjects who have not received any systematic treatment.

               2. Subjects who have received any neoadjuvant chemotherapy, adjuvant chemotherapy
                  for the purpose of curing must experience a period for at least 6 months from the
                  end of the last chemotherapy to tumor progression.

               3. Subjects with head and neck squamous cell carcinoma must have received
                  radiotherapy for the purpose of curing, and the period from the end of
                  radiotherapy to tumor progression must be at least 1 year.

               4. For subjects with gastric carcinoma, Her2 negative is required. HER2 positive is
                  defined as IHC 3+ or IHC 2+ combined with ISH+, and ISH positive is defined as
                  the ratio of the number of HER2 gene copies to the number of CEP17 signals ≥ 2.0.

          2. Results of laboratory test conducted within 7 days before enrollment must meet the
             following criteria:

               1. Neutrophils ≥ 2×109/L; WBC count ≥ 4×109L and < 15×109/L

               2. Platelets ≥ 100×109/L;

               3. Hemoglobin ≥ 90 g/L (no infusion of concentrated red blood cells within 2 weeks);

               4. Creatinine clearance rate > 60 mL/min, based on the predicted value of
                  Cockcroft-Gault glomerular filtration rate:

                  (140 - age) × (weight, kg) × (0.85, if females) 72× (serum creatinine, mg/dL) Or:
                  (140 - age) × (weight, kg) × (0.85, if females) 0.818 × (serum creatinine,
                  μmol/L)

               5. Serum total bilirubin ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN are acceptable for
                  subjects with Gilbert syndrome);

               6. INR and aPTT ≤ 1.5 × ULN, applies only to subjects who have not received
                  anticoagulation; and for subjects who are receiving anticoagulation, the dose for
                  anticoagulation must be stable.

          3. Serum pregnancy test result must be confirmed as negative for women of childbearing
             potential within 28 days prior to enrollment and the subjects must agree to take
             effective contraception measures throughout the study treatment period until 6 months
             after the end of chemotherapy or 60 days after the end of study treatment (whichever
             comes last). Women of childbearing potential are defined as women with sexual
             maturities, who meet any of the following conditions: 1) no hysterectomy or bilateral
             oophorectomy; 2) without natural menopause for a consecutive 24 months (patients with
             menopause after cancer treatment may also have childbearing potential) (i.e.
             menstruation occurred at any time during the previous consecutive 24 months) .

        Female partners of childbearing potential of the male subjects should also follow the
        contraception requirements.

        Subjects fulfilling any of the following conditions cannot be enrolled in the study:

          1. Known hypersensitivity to citric acid monohydrate, dihydrate sodium citrate, mannitol
             or polysorbate (components of the investigational drug);

          2. Anti-tumor treatment with cytotoxic drugs, biological drugs (e.g. monoclonal
             antibody), immunotherapy (e.g. interleukin 2 or interferon), or other investigational
             drugs within 4 weeks prior to enrollment;

          3. Tyrosine kinase inhibitor treatment within 2 weeks prior to enrollment;

          4. Radiotherapy within 4 weeks prior to enrollment, or radioactive drugs within 8 weeks
             prior to enrollment. However, patients receiving local palliative radiotherapy for
             bone metastasis lesions can be included;

          5. Subjects with any major surgical operation within 4 weeks prior to enrollment or who
             have not completely recovered from the prior operation (for the definition of major
             surgical operation, please refer to the Level 3 and Level 4 operations stipulated in
             the Management of Clinical Application of Medical Technology enforced on May 1, 2009);

          6. Toxicity due to any previous anticancer treatment has not recovered to CTCAE Grade
             0-1, excluding the following conditions:

               1. Alopecia;

               2. Pigmentation;

               3. Peripheral nerve toxicity recovered to < CTCAE Grade 2 (not applicable to cohort
                  5, 6, 7, and 8, subjects are not eligible if peripheral neurotoxicity does not
                  restore to normal);

               4. Long-term toxicity related to radiotherapy, which will not fully recover as
                  judged by the investigator.

          7. Central nervous system metastasis with clinical symptoms (e.g. brain edema, hormone
             intervention required, or progression of brain metastasis) and/or carcinomatous
             meningitis. Subjects with prior treatment for brain or meningeal metastasis can be
             included if they have remained stable clinically for at least 2 months and systemic
             hormone treatment (Prednisone at a dose of > 10 mg/day or other equivalent hormone
             formulations) has been discontinued for more than 4 weeks;

          8. Subjects with nasopharyngeal carcinoma or head and neck squamous cell carcinoma, who
             are found to have necrotic lesions by examination within 4 weeks prior to enrollment,
             for which there is a potential risk of massive hemorrhage as judged by the
             investigator;

          9. Previous or other concurrent malignant tumors (expect for effectively controlled
             non-melanoma skin basal cell carcinoma, breast/cervix carcinoma in situ, and other
             malignant tumors which were effectively controlled without treatment over the past 5
             years);

         10. Any active autoimmune disease or history of any autoimmune disease (including but are
             not limited to interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis,
             nephritis, hyperthyroidism or hypothyroidism. Patients with vitiligo or asthma (in
             childhood) which was completely resolved and without need of any intervention in
             adulthood can be included. However, subjects with asthma which needs bronchodilator
             for medical intervention cannot be included);

         11. Previous treatments with anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody
             or anti-CTLA-4 antibody (or any other antibody which acts on T-cell co-stimulatory or
             checkpoint pathway);

         12. Subjects diagnosed with active tuberculosis (TB), who are receiving anti-tuberculosis
             therapy or used to have anti-tuberculosis therapy within 1 year prior to screening;

         13. Concomitant diseases requiring long-term treatment with immunosuppressive drugs, or
             corticosteroids at an effective immunosuppressive dose (Prednisone at a dose of > 10
             mg/day or other equivalent hormone formulations) for systemic or local treatment
             purpose;

         14. Subjects who have received any anti-infection vaccine (e.g. influenza vaccine,
             varicella vaccine, etc.) within 4 weeks prior to enrollment;

         15. Pregnant or lactating women

         16. Positive test for HIV;

         17. Positive test for HBsAg, with HBV DNA copies detected as positive (quantitative
             measurements ≥ 1000 cps/mL);

         18. Positive test for chronic Hepatitis C in blood screening test (HCV antibody positive);
             Any other clinical significant disease or condition, which as evaluated by the
             investigator, may affect the protocol compliance, signing of inform consent form
             (ICF), or not suitable to participate into this clinical trial.
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Ruihua Xu, MD, PhD, , 

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT02915432

Organization ID

JS001-Ib-CRP-1.0


Responsible Party

Sponsor

Study Sponsor

Shanghai Junshi Bioscience Co., Ltd.


Study Sponsor

Ruihua Xu, MD, PhD, Principal Investigator, Sun Yat-sen University


Verification Date

October 2019